GSK defends itself—again—after senator argues it withdrew popular asthma med to dodge price caps and Medicaid rebates

It’s been a turbulent few days for GSK’s respiratory business: On Tuesday, the U.S. Federal Trade Commission (FTC) further cracked down on “junk patent listings,” including those related to a quartet of GSK inhalers using the company’s Ellipta device.

And now, to cap off the week, Sen. Margaret Hassan, D-New Hampshire, is calling out the British drugmaker for pulling a popular childhood asthma medication from the market in an alleged attempt to “price-gouge families.”